6505--Lymphoseek IDIQ
ID: 36C26225Q0026Type: Special Notice
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OF262-NETWORK CONTRACT OFFICE 22 (36C262)Gilbert, AZ, 85297, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/e896d380f0764a57b276a1df26a011e1/view
Timeline
    Description

    The Department of Veterans Affairs, specifically the Network Contracting Office 22, intends to award a Sole Source contract for the procurement of Lymphoseek, a proprietary radiopharmaceutical, primarily for use at the VA Loma Linda Healthcare System. This contract, designated as Solicitation Number 36C26225Q0026, will be structured as a Firm Fixed-Price Indefinite Quantity Indefinite Delivery (IDIQ) with a base year and four option years, with an estimated quantity of 86 study doses required annually. Lymphoseek is critical for identifying sentinel lymph nodes in melanoma patients, providing superior image quality due to its targeted action on the CD206 receptor. Interested parties may submit a capabilities statement by September 27, 2024, at 10:00 AM Pacific Time, and should direct inquiries to Hestia Sim at Hestia.Sim@va.gov.

    Point(s) of Contact
    Hestia SImContract Specialist
    Hesta.Sim@va.gov
    Files
    Title
    Posted
    36C26225Q0026.docx
    The Department of Veterans Affairs (VA) Network Contracting Office 22 is announcing its intent to award a Sole Source contract for the procurement of Lymphoseek, a radiopharmaceutical, primarily for the VA Loma Linda Healthcare System. This contract, identified as Solicitation Number 36C26225Q0026, will be a Firm Fixed-Price Indefinite Quantity Indefinite Delivery (IDIQ) for a base year with four option years and will be awarded to Cardinal Health 414, LLC. The sole source determination, justified under FAR 6.302-1, was made based on market research that indicated only one responsible source could meet the requirements due to the proprietary nature of Lymphoseek, which is critical for identifying sentinel lymph nodes in melanoma patients. The estimated quantity for each year is 86 study doses of Lymphoseek. This notice serves as a preliminary announcement and is not a formal solicitation, inviting potential competitors to submit evidence of capability if they believe they can meet the requirements. All inquiries should be directed to the point of contact, Hestia Sim, with responses due by September 27, 2024, at 10:00 AM Pacific Time.
    Lifecycle
    Title
    Type
    6505--Lymphoseek IDIQ
    Currently viewing
    Special Notice
    Similar Opportunities
    6505--Notice of Intent to Sole Source Pluvicto and Lutathera
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to award a sole source contract to Advanced Accelerator Applications USA for the provision of Pluvicto and Lutathera, specialized radiopharmaceuticals used in the treatment of metastatic castration-resistant prostate cancer and gastroenteropancreatic neuroendocrine tumors. This procurement is justified under FAR regulations due to the unique and highly specialized nature of the therapies required, which limits the availability of suitable suppliers. Interested parties are invited to submit their capability statements, including qualifications and relevant contract information, by 10:00 AM PT on September 25, 2024, to Peter Kim at peter.kim33@va.gov. The contracting office is located in Long Beach, CA, and responses must be submitted electronically; failure to respond may result in the contract being awarded without further solicitation.
    Q527--Intent to Sole Source Radiopharm Isotopes-Wilkes-Barre VAMC
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, through Network Contracting Office 4, intends to issue a sole source contract for the provision of Radiopharmaceutical Isotopes to the Wilkes-Barre VA Medical Center, specifically with Jubilant Draximage Radiopharmaceuticals Inc. The contract aims to ensure the timely delivery of radiopharmaceuticals that comply with U.S. Nuclear Regulatory Commission (NRC) and Food and Drug Administration (FDA) regulations, thereby prioritizing patient safety and effective healthcare for veterans. This procurement is critical for maintaining high-quality medical services, as the contractor will be required to adhere to strict quality control measures, provide emergency services, and ensure proper packaging and labeling of all materials supplied. Interested vendors must submit a capability statement by September 20, 2024, to the Contracting Specialist, Christa Stine, at christa.stine@va.gov.
    6505--Supply, Axumin-Axumin + Cerianna Medicines - Nuclear Med, CLE
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs intends to solicit and negotiate exclusively with PetNet Solutions and TrillaMed for the supply of three proprietary radiopharmaceuticals—Axumin, Amyvid, and Cerianna—for the Nuclear Medicine Service at the Louis Stokes Cleveland VA Medical Center. These products are critical for diagnosing recurrent prostate cancer, breast cancer, and Alzheimer’s disease, necessitating the use of a local radiopharmacy due to their radioactive nature and short shelf life. Interested vendors may submit their capabilities until September 18, 2024, to determine if a competitive procurement process is feasible, with all inquiries directed to Contract Specialist Don Caldwell at don.caldwell@va.gov.
    Q522--PHARMACUTICAL, STL 657-24-3-1642-0121, (VA-25-00001168)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking responses to a Sources Sought Notice for a contract involving the provision of a proprietary radiopharmaceutical agent, Pluvicto, for the St. Louis VA Medical Center. This contract will cover a base year plus four option years for the supply of Lutetium LU 177 Vipivvotide Tetraxetan, which is critical for treating adult patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. The selected contractor will be responsible for administering this radioactive diagnostic therapy via IV, with all contract administration functions retained by the Department of Veterans Affairs. Interested parties must submit their responses by September 20, 2024, at 3:00 PM CST, to Michael P. Murphy at michael.murphy7@va.gov, including their Unique Entity ID and relevant qualifications.
    6515--***EMERGENCY*** 36C242-24-AP-4714 | 528-24-4-8085-0159 Sun Nuclear Map Check - Radiation Oncology equipment Sole-Source Notice
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking to award a sole-source contract to Sun Nuclear for specialized radiation oncology equipment necessary for measuring radiation plans in brain treatment. The procurement includes critical devices such as the SRS MapCheck for stereotactic quality assurance, a StereoPHAN package for comprehensive testing, and a MultiMet WL Cube for assessing off-axis accuracy, along with a one-day on-site training session for proper equipment usage. This equipment is vital for ensuring precision in stereotactic radiation therapy, which is essential for effective patient treatment outcomes. The total funding amount for this procurement is $93,270, and interested parties should note that the response deadline is September 24, 2024, with no quotes being accepted due to the sole-source nature of the contract. For further inquiries, contact Corey Swinton, the Contracting Officer, at Corey.Swinton@va.gov.
    6505--Radiopharmaceuticals for nuclear medicine VA patients
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for an Indefinite Delivery Indefinite Quantity (IDIQ) contract to supply radiopharmaceuticals for nuclear medicine patients at the Boise VA Medical Center. The procurement aims to ensure the availability of various nuclear medicine supplies over a five-year period, starting November 1, 2024, with requirements for 24/7 availability and emergency deliveries within 90 minutes for urgent orders. This initiative is crucial for providing high-quality medical treatment to VA patients, emphasizing compliance with federal regulations and timely service delivery. Interested parties must submit their proposals by October 3, 2024, at 1:00 PM Pacific Time, and can direct inquiries to Jose E Ronstadt at jose.ronstadt@va.gov or by phone at 360-852-9885.
    6550--VISN 6 BioFire FilmArray Verification Kits.
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to negotiate a sole source contract for the procurement of BioFire FilmArray Verification Kits from Biomerieux, Inc., to meet the specialized needs of the Veterans Integrated Service Network (VISN) 6. The contract will include various diagnostic panels, with specific quantities required for each type, ensuring that the VA can provide timely and effective medical services to veterans. This procurement is critical as these specialized diagnostic supplies are only available from a single source, emphasizing the importance of maintaining compliance with federal regulations and the efficient delivery of healthcare services. Interested firms may express their capabilities to the Contract Specialist, LaToya Glover, via email by September 23, 2024, with the contract expected to be awarded effective October 1, 2024.
    6505--Ga68 PSMA Injection (Illucix)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking a contractor to provide Gallium Ga68 (Ga68-PSMA; Illucix®) radiopharmaceutical injections for the VA North Texas Health Care System, with a focus on PET imaging of prostate cancer lesions. The procurement requires contractors to possess a valid license from the US Nuclear Regulatory Commission and adhere to federal and state regulations regarding the handling and transportation of radioactive materials, ensuring safe and efficient delivery of essential medical supplies. Interested parties must submit their quotations by October 8, 2024, at 3:00 PM CST, to the designated Contract Specialist, Vance Farrell, via email, with the anticipated delivery period set from October 25, 2024, to October 24, 2025.
    6515--OptiLight
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Veterans Health Administration and Network Contracting Office 6, intends to award a sole-source contract to Milling Medical LLC for the procurement of the Lumenis OptiLight system, a specialized FDA-approved treatment for dry eyes. The contract will involve the delivery of Lumenis BE OptiLight equipment and a Treatment Kit to the Fredericksburg HealthCare Clinic in Virginia, with the effective contract date set for September 15, 2024. This procurement is critical as the Lumenis OptiLight is the only product of its kind that meets the government's needs for treating dry eyes, as determined through market research. Interested vendors have a limited window of three days to submit capability statements to the contracting officer, Gordon E. Burns, via email at Gordon.Burns@va.gov, with no obligation for the government to procure the services mentioned.
    6640--Benchtop flow cytometer Intent to Sole Source
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 6, intends to award a sole source Firm-Fixed-Price purchase order for an Accuri C6 Plus system from Becton, Dickinson and Company (BD Biosciences). This procurement is aimed at acquiring specialized instruments intended solely for research purposes, not for diagnostic or therapeutic use, highlighting the need for proprietary equipment in the VA's operational framework. Interested parties are invited to demonstrate their capability to meet this requirement by submitting supporting evidence by September 20, 2024, at 4 PM EST, with all inquiries directed to Contracting Officer Jamie Sullivan via email at jamie.sullivan4@va.gov.